Hulyo 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
Ang ACT Therapeutics at GenScript ProBio ay nasa proseso ng pagpirma ng isang kontrata para sa pagbuo at paggawa ng plasmid at virus vectors para sa unang pipeline ng Advanced CAR-T Platform (ACT platform) ng ACT Therapeutics, na iaatas din sa paggawa ng mga hilaw na materyales para sa mga kasunod na pipeline ng ACT Therapeutics. Sasaklawin ng kontrata ang paggawa ng mga plasmid at virus vector para sa unang pipeline ng Advanced CAR-T Platform ng ACT Therapeutics.
Bilang resulta ng kasunduang ito, ang GenScript ProBio ay itinaas sa katayuan ng isang pandaigdigang kasosyo na kayang suportahan ang mga platform ng ACT para sa mga therapeutic ng ACT.
Ang ACT platform ay isang susunod na henerasyong teknolohiya ng cell at gene therapy na nagta-target ng mga antigen ng kanser sa pamamagitan ng pagpasok ng mga gene na idinisenyo upang i-target ang mga antigen na iyon sa mga immune cell. Ang mga gene na ito ay inihahatid sa mga immune cell sa pamamagitan ng paggamit ng mga virus vector. Ang GenScript ProBio ay nagtataglay ng mataas na kalidad na pag-develop ng proseso ng virus vector at isang one-stop na platform ng serbisyo para sa produksyon ng GMP, na parehong kinakailangan para sa pagbuo ng cell at gene therapy.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing kanser sa dugo. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO of GenScript ProBio, said, “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
Sinabi ni Seogkyoung-Kong, CEO ng ACT Therapeutics, "Nakumpleto na namin ang mga paghahanda para sa platform ng ACT na lumabas sa buong mundo sa pamamagitan ng isang strategic partnership sa GenScript ProBio. Pabilisin namin ang pagbuo ng mga paggamot na nagta-target ng mga matigas at hindi maaalis na mga solidong kanser."
Tungkol sa GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
Patungo sa misyon ng "Innovation through Collaboration", ang GenScript ProBio ay nakatuon sa pagtulong sa mga customer na paikliin ang timeline para sa pagbuo ng mga biological na gamot mula sa pagtuklas hanggang sa komersyalisasyon, na makabuluhang nagpapababa ng mga gastos sa R&D at pagbuo ng mas malusog na hinaharap.
